Biopharma clinical development veteran to propel Opus’ AAV-b…
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.

The RD Fund is changing how the world treats blinding retinal diseases.
Click here to download the January 2021 Outcomes & Outlook Report.

IN THE NEWS
Trial recruitment is enabled by the Foundation Fighting Blin…
20-year biopharma industry veteran to lead manufacturing for…
ProQR has published the top-line results from the Phase 2/3 …
Media Contact:
Chris Adams
Vice President, Marketing & Com…
Media Contact:
Chris Adams
410-423-0585
cadams@fightingblindnes…
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — SalioGen …
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (G…
Paris, December 9, 2021 – SparingVision, a genomic medicine …
LONDON—(BUSINESS WIRE)—Dec 6, 2021—Gyroscope Therapeutics Ho…
by Jason Parker, WRAL TechWire
RALEIGH – Opus Genetics recen…
Opus Genetics announced an agreement to license its third pr…